Treatment Options and Therapeutics for Non-small Cell Lung Cancer
Deadline for manuscript submissions: closed (30 September 2020) | Viewed by 38920
The treatment of non-small cell lung cancer (NSCLC) has heralded an era of precision medicine based on the detection of mutated driver kinases and the development of specific inhibitors targeting altered EGFR receptors, rearranged anaplastic lymphoma kinase (ALK), ROS1, MET, and a host of other minor oncogenic proteins. Knowledge of the 3D structure of the mutated kinases allowed for rational drug design fitting therapeutics mostly to the ATP binding pocket of the enzymes. Clinical administration of these tyrosine kinase inhibitors (TKIs) results in prolonged survival of up to several years of the subpopulation of patients expressing suitable molecular markers. However, drug resistance invariably develops and the affected patients have to be treated with new drugs targeting secondary mutations or bypass pathways. Accordingly, for mutated EGFR and rearranged ALK, several TKIs are approved and can be applied in sequence and a host of new compounds are in preclinical testing and early trials. The pipeline of new drugs comprises various multi-kinase inhibitors, inhibitors to oncogenic proteins that exhibit activating mutations, overexpression, gene amplification, and translocations, as well as novel agents directed to formerly “undruggable” targets such as KRAS, which is frequently mutated in NSCLC.
This Special Issue of Pharmaceuticals on “Treatment Options and Therapeutics for Non-Small Cell Lung Cancer” will include both regular articles and reviews focused on the most recent advances in the development of targeted pharmaceuticals active against NSCLC. Submissions should deal with the development and application of novel agents showing potential improvements in several aspects including broadened target profiles, overcoming resistance mechanisms, and lower toxicity for the treatment of NSCLC.
Prof. Gerhard Hamilton
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- non-small cell lung cancer
- targeted therapy
- tyrosine kinase inhibitors
- drug resistance
- crystal structure
- drug combinations
- New Therapies for Hepatocellular Carcinoma in Pharmaceuticals (6 articles)
- Malignant Glioma: Novel Therapeutic Strategies in Pharmaceuticals (7 articles)
- Cancer Translational Biomarkers and Targeted Therapies in Pharmaceuticals (16 articles)
- Clinical Development of Cancer Treatment in Pharmaceuticals (5 articles)
- Anticancer Drugs in Pharmaceuticals (10 articles)